Evidence map›Paper›PMID 25756515›Full record

ArticleCancer biology & therapy2015

Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.

Masaaki Takai, Takatoshi Nakagawa, Akiko Tanabe, Yoshito Terai, Masahide Ohmichi, Michio Asahi

Open access · hybridAbstract read
In one paragraph

Article in Cancer biology & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Targeting PP2A in cancer: an underrated option.Journal of experimental & clinical cancer research : CR · 2025
    Review
  2. Review
  3. Article
  4. Resibufogenin inhibits ovarian clear cell carcinoma (OCCC) growthAmerican journal of translational research · 2019
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Masaaki Takaia Department of Obstetrics and Gynecology ; Faculty of Medicine; Osaka Medical College , Osaka , Japan.
Takatoshi Nakagawa
Akiko Tanabe
Yoshito Terai
Masahide Ohmichi
Michio Asahi
Osaka Medical and Pharmaceutical University · JPFaculty (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia-inducible factor-1 (HIF-1) is one of the most promising pharmacological targets for all types of cancer, including ovarian cancer. Ovarian clear cell carcinoma (OCCC) has poor prognosis because of its insensitivity to chemotherapy. To elucidate the characteristics of this troublesome cancer, we examined HIF-1α expression under normoxia or hypoxia in various ovarian cancer cell lines. HIF-1α was highly expressed under normoxia only in RMG-1, an OCCC cell line. To examine whether HIF-1 is involved in the tumorigenesis of RMG-1 cells, we established HIF-1α-silenced cells, RMG-1HKD. The proliferation rate of RMG-1HKD cells was faster than that of RMG-1 cells. Furthermore, the activity of MEK/ERK in the Ras pathway increased in RMG-1HKD cells, whereas that of mTOR in the PI3K pathway did not change. Activation of the Ras pathway was attributable to the increase in phosphorylated MEK via PP2A inactivation. To confirm the crosstalk between the PI3K and Ras pathways in vivo, RMG-1 or RMG-1HKD cells were transplanted into the skin of nude mice with rapamycin (an inhibitor of mTOR), PD98059 (an inhibitor of MEK), or both. RMG-1HKD cells showed higher sensitivity to PD98059 than that observed in RMD-1 cells, whereas the combination therapy resulted in synergistic inhibition of both cells. These findings suggest that inhibition of HIF-1, a downstream target of mTOR in the PI3K pathway, activates the Ras pathway on account of the increase in MEK phosphorylation via PP2A inactivation, and the crosstalk between the 2 pathways could be applied in the combination therapy for HIF-1-overexpressing cancers such as OCCC.

Indexed as

Signal TransductionAdenocarcinoma, Clear CellAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitMiceMitogen-Activated Protein KinasesOvarian NeoplasmsOxygen ConsumptionPhosphatidylinositol 3-KinasesPhosphorylationHypoxia-Inducible Factor 1, alpha SubunitMitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsProtein Phosphatase 2Proto-Oncogene Proteins p21(ras)SirolimusTOR Serine-Threonine Kinases4E-BP, eukaryotic initiation factor 4E-binding-proteinERK, extracellular signal-regulated kinaseHIF-1HIF-1, hypoxia-inducible factor-1MEK inhibitorMEK, mitogen-activated kinase/extracellular signal-regulated kinase kinasemTORmTOR, mammalian target of rapamycinOCCC, ovarian clear cell carcinomaOE, ovarian endometrioid carcinomaOM, ovarian mucinous carcinomaOS, ovarian serous carcinomaovarian clear cell carcinomaPI3K pathwayPI3K, phosphatidylinositol 3-kinasePP2APP2A, protein phosphatase 2ApVHL, von Hippel–Lindau proteinRas pathwayRCCC, renal clear cell carcinomaRCC, renal cell carcinomaS6K, p70 ribosomal S6 kinase

Identifiers

PMID25756515
PMCPMC4622433
OpenAlexW1490748999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.